Kailera Therapeutics Inc. (KLRA:NASDAQ) closed at $12.89 on October 20, 2026, up 12.77% on the day. The stock trades 54.3% below its 52-week high of $28.23 and 32.1% above its 52-week low of $9.76. Over the past year, it lost 56.0%. Kailera Therapeutics Inc. is part of the Health Care sector.
In 128 trading sessions since April 20, 2026, KLRA closed higher on 58 days (45%). Its best day was October 9, 2026 (+16.10%) and its worst was August 28, 2026 (-12.52%). The stock moved 10% or more in a single session 5 times.
Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape. Kailera's lead product candidate, ribupatide (also known as KAI-9531), is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist that has the potential for the greatest weight loss. Kailera is expanding the ribupatide franchise by developing a once-daily oral tablet formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability.
Find more stocks like KLRA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.